WVE Wave Life Sciences
- 5.940
- +0.060+1.02%
Wave Life Sciences News
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Wave Life Sciences' WVE-006 Advancements: A Buy Rating on Gene Editing Innovations and Strategic Partnerships
Buy Rating Affirmed: Wave Life Sciences's Promising Future With Clinical Milestones and Strategic GSK Partnership
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)
Buy Rating Affirmed: Strategic Partnerships and Clinical Milestones Propel Wave Life Sciences' Growth Potential
Wave Life Sciences: A Promising Buy Rating Based on Strategic GSK Collaboration and Innovative SiRNA Platform
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in SiRNA and RNA Editing
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
Wave Life Sciences(WVE.US) Officer Sells US$96,421.47 in Common Stock
$Wave Life Sciences(WVE.US)$ Officer Moran Kyle sold 15,630 shares of Common Stock on Apr 3, 2024 at an average price of $6.169 for a total value of $96,421.47.Source: Announcement What is statement o
GRIN, WOOF and MRNS Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
Wave Life Sciences Price Target Maintained With a $17.00/Share by Truist Securities
Wave Life Sciences Price Target Maintained With a $17.00/Share by Truist Securities
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
Wave Life Sciences Is Maintained at Buy by Mizuho
Wave Life Sciences Is Maintained at Buy by Mizuho
Mizuho Maintains Buy on WAVE Life Sciences, Raises Price Target to $19
Mizuho analyst Salim Syed maintains WAVE Life Sciences with a Buy and raises the price target from $10 to $19.
Analysis
Price Target
No Data
